Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

PARIS, Oct 17 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Thursday it was "surprised" by a renewed, higher offer for its consumer arm Opella from private equity firm PAI ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

PARIS (Reuters) -Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical ...

After the fall of communism in 1989, Budapest emerged as one of the most enchanting destinations in central Europe, buzzing with spectacular landmarks, Michelin-starred restaurants, imposing Belle ...

Oct 10 (Reuters) - Denali Therapeutics (DNLI.O), opens new tab said on Thursday its partner Sanofi (SASY.PA), opens new tab has discontinued a mid-stage study testing their experimental drug to ...

Sanofi’s shares traded 0.2% lower on Monday morning in Paris. The stock has risen about 2% over the past 12 months. Despite the commitments it faces in France, CD&R has been drawn to the Sanofi ...